scholarly journals Effect of early postextubation high-flow nasal cannula vs conventional oxygen therapy on hypoxaemia in patients after major abdominal surgery: a French multicentre randomised controlled trial (OPERA)

2016 ◽  
Vol 42 (12) ◽  
pp. 1888-1898 ◽  
Author(s):  
Emmanuel Futier ◽  
◽  
Catherine Paugam-Burtz ◽  
Thomas Godet ◽  
Linda Khoy-Ear ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Abdominal Surgery ◽  
Oxygen Therapy ◽  
Controlled Trial ◽  
High Flow ◽  
Nasal Cannula ◽  
Major Abdominal Surgery ◽  
High Flow Nasal Cannula ◽  
Randomised Controlled

scholarly journals Effects of flow rate on transnasal pulmonary aerosol delivery of bronchodilators via high-flow nasal cannula for patients with COPD and asthma: protocol for a randomised controlled trial

BMJ Open ◽  
2019 ◽  
Vol 9 (6) ◽  
pp. e028584
Author(s):  
Jie Li ◽  
Jian Luo ◽  
Yibing Chen ◽  
Lixing Xie ◽  
James B Fink
Keyword(s):  
Randomised Controlled Trial ◽  
Gas Flow ◽  
Controlled Trial ◽  
High Flow ◽  
Nasal Cannula ◽  
Dose Inhaler ◽  
High Flow Nasal Cannula ◽  
Fill Volume ◽  
Randomised Controlled

IntroductionBoth in vitro and in vivo radiolabelled studies on nebulisation via high-flow nasal cannula showed that inhaled dose decreases as the administered gas flow increases. In our previous in vitro study, we investigated the effects of the ratio of gas flow to subject’s peak inspiratory flow (GF:IF) on the aerosol deposition, which increased as the GF:IF decreased, with an optimal GF:IF between 0.1 and 0.5 producing a stable ‘lung’ deposition in both quiet and distressed breathing. Thus, we aim to validate our in vitro findings in subjects with reversible airflow limitations by assessing their response to inhaled bronchodilator.Methods and analysisThis is a single-centre, randomised controlled trial. Subjects with chronic obstructive pulmonary disease or asthma with positive response to 400μg albuterol via metered dose inhaler and valved holding chamber will be enrolled and consented. After a washout period (1–3 days), subjects will be randomly assigned to inhale albuterol with one of three gas flows: 50 L/min, GF:IF=1.0 and GF:IF=0.5. In each arm, subjects will inhale 2 mL saline, followed by escalating doubling doses (0.5, 1, 2 and 4 mg) of albuterol in a fill volume of 2 mL, delivered by a vibrating mesh nebuliser via heated nasal cannula set up at 37°C. An interval of 30 min between each dose of albuterol, with spirometry measured at baseline and after each inhalation. Titration will be terminated if forced expiratory volume in 1 s improvement is <5%, or adverse event is observed.Ethics and disseminationThis trial has been approved by the Ethic Committee of People’s Liberation Army General Hospital, Beijing, China (no. S2018-200-01). The results will be disseminated through peer-reviewed journals, national and international conferences.Trial registration numberNCT03739359; Pre-results.

High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial

The Lancet ◽  
2017 ◽  
Vol 389 (10072) ◽  
pp. 930-939 ◽  
Author(s):  
Elizabeth Kepreotes ◽  
Bruce Whitehead ◽  
John Attia ◽  
Christopher Oldmeadow ◽  
Adam Collison ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
High Flow ◽  
Nasal Cannula ◽  
Low Flow ◽  
Open Phase ◽  
Randomised Controlled

High-flow nasal cannula oxygen therapy for outpatients undergoing flexible bronchoscopy: a randomised controlled trial

Thorax ◽  
2021 ◽  
pp. thoraxjnl-2021-217116
Author(s):  
Federico Longhini ◽  
Corrado Pelaia ◽  
Eugenio Garofalo ◽  
Andrea Bruni ◽  
Roberta Placida ◽  
...  
Keyword(s):  
Gas Exchange ◽  
Lung Volume ◽  
Controlled Trial ◽  
Blood Gases ◽  
High Flow ◽  
Nasal Cannula ◽  
Flexible Bronchoscopy ◽  
High Flow Nasal Cannula ◽  
Arterial Blood ◽  
Randomised Controlled

IntroductionHigh-flow nasal cannula (HFNC) provides benefits to patients undergoing flexible bronchoscopy (FOB). We compared the effects of HFNC versus standard therapy (ST) on gas exchange, lung volume and diaphragm function in patients undergoing FOB for bronchoalveolar lavage (BAL).Methods36 outpatients were randomised to ST or HFNC. Arterial blood gases, episodes of severe desaturation, changes of end-expiratory lung impedance (ΔEELI), diaphragm ultrasound were recorded. Measurements were done at baseline (T0), after bronchoscope insertion (T1), at the end of the procedure (T2) and 10 min afterwards (T3).ResultsArterial partial oxygen pressure (PaO2) was not different between T0 (10.8 (95% CI 8.7 to 12.0) kPa and T2 (11.1 (95% CI 10.4 to 12.0) kPa) with HFNC, while decreased from 11.1 (95% CI 10.5 to 12.1) to 9.1 (95% CI 8.4 to 9.8) kPa with ST. At T2, PaO2 was significantly higher with HFNC than with ST (p<0.001). Also, with HFNC, compared with ST, fewer desaturations occurred (11% vs 56%; p<0.01). ΔEELI was no different at the different time points with HFNC, while with ST there was a significant decrease at T1 (−170 (95% CI −382 to −32) mL, p=0.003), T2 (−211 (95% CI −425 to −148) mL, p<0.001) and T3 (−213 (95% CI −398 to −81) mL, p<0.001), as opposed to T0. EELI was lower with ST than HFNC at T1 (p=0.006), T2 (p=0.001) and T3 (p=0.002). Diaphragm displacement was no different between groups (p=0.748), while the thickening fraction significantly increased at T1 and T2 with ST only (p<0.01).ConclusionsDuring FOB for BAL, HFNC improves gas exchange, avoiding loss of end-expiratory lung volume and preventing increase of diaphragm activation.Trial registration numberNCT04016480.

Sign in / Sign up

Export Citation Format

Share Document